As an independent consultant working with Carnegie Park Capital, I support private equity sponsors, venture capital investors and SPAC teams as an extension of their deal teams. Since 2022, I’ve built operating models, revenue forecasts, valuations and transaction analyses for companies with enterprise values of roughly $500M to $2B+.
In healthcare and biopharma, I rebuilt an oncology asset’s commercial opportunity from epidemiology and valued it using DCF. I also developed an eight-country cancer-screening market size, linking demand assumptions to revenue, EBITDA and valuation scenarios.
For de-SPAC transactions, I translated term sheets into models of conversion mechanics, price resets, bridge tranches, investor returns and pro forma dilution. With SparkLabs Acquisition Corp. and affiliated SPAC teams, I supported evaluation of five targets through financial modelling, market research, valuation and capital-structure analysis.
At Rocsearch India Pvt. Ltd., I analysed more than 100 SPAC transactions and performed founder share valuations using option-pricing and regression-based methods. Earlier, as an Article Assistant at Sharp & Tannan | Mandeep Kumar Garg & Co., I prepared CMA reports and projected financial statements, and supported audits, GST implementation and ROC compliance.
